Skip to Content

Tag: Obstructive Sleep Apnea (OSA)


Also Noted

Inspire Medical Systems gets green light for V 

August 5, 2024HME News Staff

MINNEAPOLIS – Inspire Medical Systems has announced approval from the U.S. Food and Drug Administration for the Inspire V therapy system, which includes a next generation neurostimulator for the treatment of obstructive sleep apnea. The system also includes the associated Bluetooth patient remote and physician programmer. “We are thrilled to announce the FDA approval of our next generation Inspire neurostimulation system,” said Tim Herbert, chairman and CEO of Inspire Medical Systems....

CPAP Alternative, Inspire Medical Systems, Obstructive Sleep Apnea (OSA)


Read Full Articlered right arrow icon

Also Noted

sovaSage promotes Caputo 

July 8, 2024HME News Staff

PITTSBURGH – sovaSage, a company specializing in AI-based software and services for the management of obstructive sleep apnea, has promoted Jamie Caputo to vice president of sales. Caputo has played a key role in driving the roll out of two products: an AI-based software platform designed to select and fit the best CPAP mask for patients; and TherapistAssist Jeanie, a virtual sleep coach and compliance management platform that’s augmented with live support sleep coaches and respiratory...

Adherence, Artificial Intelligence (AI), CPAP Mask, Jamie Caputo, Obstructive Sleep Apnea (OSA), sovaSage


Read Full Articlered right arrow icon

Eli Lilly says tirzepatide reduces OSA severity 

Specialty Providers

Eli Lilly says tirzepatide reduces OSA severity 

June 24, 2024HME News Staff

INDIANAPOLIS – Eli Lilly’s tirzepatide demonstrated a mean reduction of up to 62.8% on the apnea-hypopnea index (AHI), or about 30 fewer events restricting or blocking a person's airflow per hour of sleep, compared to placebo, according to the company’s SURMOUNT-OSA phase 3 clinical trials evaluating the drug for the treatment of moderate-to-severe obstructive sleep apnea in adults with obesity, with and without CPAP therapy.  In a key secondary endpoint, the company...

CPAP Therapy, Eli Lilly, Obstructive Sleep Apnea (OSA), Tirzepatide


Read Full Articlered right arrow icon

Also Noted

Mount Sinai 'poised to shift paradigm’ on sleep testing, therapy 

February 13, 2024HME News Staff

NEW YORK – Mount Sinai researchers have been awarded a five-year, $4.1 million grant from the National Heart, Lung and Blood Institute at the National Institutes of Health to develop and study an artificial intelligence-powered model that predicts adverse outcomes of obstructive sleep apnea. Researchers say their model will better reflect the underlying physiology of the condition and the ways it impairs sleep, improving patient care and treatment. “Our proposal uses a state-of-the-art,...

Artificial Intelligence (AI), Mount Sinai, Obstructive Sleep Apnea (OSA)


Read Full Articlered right arrow icon

Also Noted

Apnimed makes critical additions to C-suite 

January 22, 2024HME News Staff

CAMBRIDGE, Mass. – Apnimed, a clinical-stage pharmaceutical company focused on developing oral pharmacological therapies for the treatment of obstructive sleep apnea and related disorders, has named Graham Goodrich as chief commercial officer and Ted Harding as chief human resources officer. The company says the additions to the C-suite are critical as the company prepares to launch AD109, a potential nighttime oral treatment currently in Phase 3. “We are thrilled to have attracted two...

Apnimed, Graham Goodrich, Obstructive Sleep Apnea (OSA), oral therapy, Ted Harding


Read Full Articlered right arrow icon

Dr. Paruthi on thoughtful approach to trackers 

Specialty Providers

Dr. Paruthi on thoughtful approach to trackers 

December 20, 2023Theresa Flaherty, Managing Editor

YARMOUTH, Maine – Using health trackers to monitor sleep has become almost as common as using them to count steps, but they can be limited, especially when it comes to serious problems like obstructive sleep apnea, says Dr. Shalini Paruthi.  “I think we just have to really thoughtfully interpret the data we're getting from these and look for patterns because that can be really helpful,” said Paruthi, a sleep medicine physician and spokesperson for the American Academy...

American Academy of Sleep Medicine (AASM), Obstructive Sleep Apnea (OSA), Shalini Paruthi, sleep tracker


Read Full Articlered right arrow icon

Also Noted

FDA clears Vivos device for OSA

November 30, 2023HME News Staff

LITTLETON, Colo. – Vivos Therapeutics has received 510(k) clearance from the U.S. Food and Drug Administration for treating severe obstructive sleep apnea in adults using its removable CARE (Complete Airway Repositioning and/or Expansion) oral appliances. CARE appliances include the flagship DNA oral appliance, the mRNA oral appliance and the mmRNA oral appliance. “This achievement is a pivotal milestone for Vivos and elevates our proven treatment options right into the mainstream of...

Obstructive Sleep Apnea (OSA), Oral appliance, Vivos


Read Full Articlered right arrow icon

Also Noted

Apnimed enters JV with Shionogi 

November 20, 2023HME News Staff

CAMBRIDGE, Mass. – Apnimed, a clinical-stage pharmaceutical company focused on developing oral pharmacological therapies for the treatment of obstructive sleep apnea, has announced a joint venture with Shionogi & Co., a pharmaceutical company based in Japan, to develop therapies to treat OSA and other sleep disorders. The joint venture, Shionogi-Apnimed Sleep Science, combines Apnimed’s deep knowledge of OSA, highly experienced clinical-stage drug development team and robust network of...

Apnimed, Joint Venture, Obstructive Sleep Apnea (OSA)


Read Full Articlered right arrow icon

Also Noted

Gem Health raises $5M for sleep apnea biz 

September 18, 2023HME News Staff

MINNEAPOLIS – Gem Specialty Health, whose first offering, GEM SLEEP, provides an end-to-end solution for obstructive sleep apnea, has raised $5 million. The seed financing round, led by HealthTrend Capital, with participation from existing investor Base10 Partners and new investor Mairs & Power Venture Capital, will allow the company to expand payment options by offering insurance coverage through more local and national health plans, making convenient care affordable to millions. “We...

Diagnosis, GEM SLEEP, Gem Specialty Care, Obstructive Sleep Apnea (OSA), treatment


Read Full Articlered right arrow icon

Also Noted

ProSomnus says OAT therapy as effective as CPAP

August 23, 2023HME News Staff

PLEASANTON, Calif. – Precision oral appliance therapy was effective among 90% of moderate and 85% of severe OSA patients during a recent study, says ProSomus, maker of the ProSomnus EVO. The company’s First Line Obstructive Sleep Apnea Treatment (FLOSAT) study looked at 136 patients to compare the effectiveness of precision OAT vs. CPAP therapy. Key findings to date include: Precision oral appliance therapy is effective, and non-inferior to CPAP, as a first-line treatment for moderate...

Obstructive Sleep Apnea (OSA), ProSomnus


Read Full Articlered right arrow icon